Freelance science journalist, covering drugs, clinical trials, biotech, pharma and more. Writes for Nature, The Lancet, The New Scientist, and others.

Search Tweets

Twitter Feed

@AsherMullard — 512 followers, 196 tweets

May 04, 2017

@ChristosArgyrop @NEJM Of course. But @akesselheim suggests here that without a high FDA bar, firms may not pull the plug in similar situations - with high costs.

May 01, 2017

RT @NatRevDrugDisc: 9 paths to PCSK9 inhibition: genetics-validated target as testing ground for new platforms 

Show more